Abstract

Non-alcoholic fatty liver disease (NAFLD) is a prevalent, multifactorial, and poorly understood liver disease with an increasing incidence worldwide. NAFLD is typically asymptomatic and coupled with other symptoms of metabolic syndrome. The prevalence of NAFLD is rising in tandem with the prevalence of obesity. In the Western hemisphere, NAFLD is one of the most prevalent causes of liver disease and liver transplantation. Recent research suggests that gut microbiome dysbiosis may play a significant role in the pathogenesis of NAFLD by dysregulating the gut-liver axis. The so-called "gut-liver axis" refers to the communication and feedback loop between the digestive system and the liver. Several pathological mechanisms characterized the alteration of the gut-liver axis, such as the impairment of the gut barrier and the increase of the intestinal permeability which result in endotoxemia and inflammation, and changes in bile acid profiles and metabolite levels produced by the gut microbiome. This review will explore the role of gut-liver axis disruption, mediated by gut microbiome dysbiosis, on NAFLD development.

MeSH

Liver Diseases, Dysbiosis, Non-Alcoholic Fatty Liver Disease, Liver, Alcoholics, Prevalence, Obesity, Fatty Liver, Gastrointestinal Microbiome, Fatty Liver, Alcoholic

Cited by

• Microbiome Dysbiosis: A Pathological Mechanism at the Intersection of Obesity and Glaucoma. Int J Mol Sci, 2023
• Pathological Evolution and Internal Medicine Management of Nonalcoholic Fatty Liver Disease (NAFLD) in the Era of Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD). Cureus, 2025
• Role of Perturbated Hemostasis in MASLD and Its Correlation with Adipokines. Life (Basel), 2024
• The Impact of Probiotic on Liver Diseases and the Microbiota. Life (Basel), 2024
• The Gut-Organ Axis within the Human Body: Gut Dysbiosis and the Role of Prebiotics. Life (Basel), 2023
• Role of gut-brain axis dysregulation in the pathogenesis of non-alcoholic fatty liver disease: mechanisms and therapeutic implications. Am J Transl Res, 2025
• Role of fecal microbiota transplant in management of hepatic encephalopathy: Current trends and future directions. World J Hepatol, 2024
• Gut-Liver Axis: The Role of Intestinal Microbiota and Their Metabolites in the Progression of Metabolic Dysfunction-Associated Steatotic Liver Disease. Gut Liver, 2025
• Heyndrickxia coagulans SANK70258 supplementation improves growth performance, gut health, and liver function in growing pigs. Front Vet Sci, 2025
• MASLD development: From molecular pathogenesis toward therapeutic strategies. Chin Med J (Engl), 2025
• Protective Effects of Plum on Liver and Gut Injury in Metabolic Dysfunction-Associated Fatty Liver Disease. Nutrients, 2024
• Fecal Metagenomics and Metabolomics Identifying Microbial Signatures in Non-Alcoholic Fatty Liver Disease. Int J Mol Sci, 2023
• Exploring public interest in gut microbiome dysbiosis, NAFLD, and probiotics using Google Trends. Sci Rep, 2024
• The Role of in Liver Diseases: A Systematic Review of Next-Generation Sequencing Studies. Microorganisms, 2023
• New Insights into the Pathogenesis of Metabolic-Associated Fatty Liver Disease (MAFLD): Gut-Liver-Heart Crosstalk. Nutrients, 2023